H

Huakang Biomedical Holdings Co Ltd
HKEX:8622

Watchlist Manager
Huakang Biomedical Holdings Co Ltd
HKEX:8622
Watchlist
Price: 0.164 HKD 1.86% Market Closed
Market Cap: 82.1m HKD
Have any thoughts about
Huakang Biomedical Holdings Co Ltd?
Write Note

Huakang Biomedical Holdings Co Ltd
Revenue

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Huakang Biomedical Holdings Co Ltd
Revenue Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Revenue CAGR 3Y CAGR 5Y CAGR 10Y
H
Huakang Biomedical Holdings Co Ltd
HKEX:8622
Revenue
ÂĄ24.6m
CAGR 3-Years
4%
CAGR 5-Years
-3%
CAGR 10-Years
N/A
K
Kaisa Health Group Holdings Ltd
HKEX:876
Revenue
HK$181.8m
CAGR 3-Years
-5%
CAGR 5-Years
-5%
CAGR 10-Years
-6%
K
Kelfred Holdings Ltd
HKEX:1134
Revenue
HK$393.3m
CAGR 3-Years
4%
CAGR 5-Years
-1%
CAGR 10-Years
N/A
Arts Optical International Holdings Ltd
HKEX:1120
Revenue
HK$1.2B
CAGR 3-Years
10%
CAGR 5-Years
1%
CAGR 10-Years
-2%
O
OrbusNeich Medical Group Holdings Ltd
HKEX:6929
Revenue
$153.9m
CAGR 3-Years
20%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Huakang Biomedical Holdings Co Ltd
Glance View

Market Cap
82.1m HKD
Industry
Health Care

Huakang Biomedical Holdings Co. Ltd. operates as a medical group company. The company employs 83 full-time employees The company went IPO on 2018-12-13. The IVD reagents include male fertility IVD reagents, Epstein-Barr virus antibody detection reagents ad parasite antibody detection reagents, among others. The male fertility IVD reagents include sperm function test products, accessory genital glands test products, anti-sperm antibody test products, as well as male reproductive tract infection test products, among others. In addition, the Company is also involved in the sale of auxiliary reproductive supplies and equipments, such as glass coverslips and sperm sample collection cups.

Intrinsic Value
0.085 HKD
Overvaluation 48%
Intrinsic Value
Price
H

See Also

What is Huakang Biomedical Holdings Co Ltd's Revenue?
Revenue
24.6m CNY

Based on the financial report for Dec 31, 2023, Huakang Biomedical Holdings Co Ltd's Revenue amounts to 24.6m CNY.

What is Huakang Biomedical Holdings Co Ltd's Revenue growth rate?
Revenue CAGR 5Y
-3%

Over the last year, the Revenue growth was -3%. The average annual Revenue growth rates for Huakang Biomedical Holdings Co Ltd have been 4% over the past three years , -3% over the past five years .

Back to Top